ADGRE5

Across TCGA pan-cancer cohorts, ADGRE5 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ADGRE5 data layer compared with 21 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ADGRE5 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ADGRE5 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

PDAC, HNSC, and UCEC are the cancer types where ADGRE5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	All	0.755	0.433	.004	34	view →
HNSC	DFS	Median	II,III,IV	0.897	0.993	.005	10	view →
UCEC	DFS	Quartile	II,III,IV	0.487	1.000	.031	4	view →
LUAD	OS	Quartile	III,IV	0.347	0.746	.022	3	view →
LSCC	OS	Quartile	II,III,IV	0.604	0.939	.030	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ADGRE5–PDAC (OS)

Open the PDAC breakdown →